181 related articles for article (PubMed ID: 38014945)
1. Population pharmacokinetic modeling and target attainment analyses of rezafungin for the treatment of candidemia and invasive candidiasis.
Roepcke S; Passarell J; Walker H; Flanagan S
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0091623. PubMed ID: 38014945
[TBL] [Abstract][Full Text] [Related]
2. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
Bader JC; Lakota EA; Flanagan S; Ong V; Sandison T; Rubino CM; Bhavnani SM; Ambrose PG
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555634
[TBL] [Abstract][Full Text] [Related]
3. Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections.
Rubino CM; Flanagan S
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084221. PubMed ID: 34398673
[TBL] [Abstract][Full Text] [Related]
4. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data.
Lakota EA; Ong V; Flanagan S; Rubino CM
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555631
[TBL] [Abstract][Full Text] [Related]
6. Rezafungin: a novel antifungal for the treatment of invasive candidiasis.
Ham YY; Lewis JS; Thompson GR
Future Microbiol; 2021 Jan; 16(1):27-36. PubMed ID: 33438477
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis.
Sharma D; Vazquez JA
Expert Opin Pharmacother; 2024 Mar; 25(4):339-347. PubMed ID: 38497379
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and
Miesel L; Cushion MT; Ashbaugh A; Lopez SR; Ong V
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318018
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
10. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix.
August BA; Kale-Pradhan PB
Pharmacotherapy; 2024 Jun; 44(6):467-479. PubMed ID: 38721866
[TBL] [Abstract][Full Text] [Related]
11. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy.
Miesel L; Lin KY; Ong V
Pharmacol Res Perspect; 2019 Dec; 7(6):e00546. PubMed ID: 31763045
[TBL] [Abstract][Full Text] [Related]
12. Invasive
Oliva A; De Rosa FG; Mikulska M; Pea F; Sanguinetti M; Tascini C; Venditti M
Expert Rev Anti Infect Ther; 2023; 21(9):957-975. PubMed ID: 37494128
[TBL] [Abstract][Full Text] [Related]
13. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
14. Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481440
[TBL] [Abstract][Full Text] [Related]
15. Metabolism, Excretion, and Mass Balance of [
Ong V; Wills S; Watson D; Sandison T; Flanagan S
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0139021. PubMed ID: 34662192
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR; Soriano A; Honore PM; Bassetti M; Cornely OA; Kollef M; Kullberg BJ; Pullman J; Hites M; Fortún J; Horcajada JP; Kotanidou A; Das AF; Sandison T; Aram JA; Vazquez JA; Pappas PG
Lancet Infect Dis; 2024 Mar; 24(3):319-328. PubMed ID: 38008099
[TBL] [Abstract][Full Text] [Related]
17. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model.
Lepak AJ; Zhao M; Andes DR
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181375
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.
Liu P
Antimicrob Agents Chemother; 2013 Jan; 57(1):466-74. PubMed ID: 23129052
[TBL] [Abstract][Full Text] [Related]
20. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
